Valbiotis SA

Paris Stock Exchange ALVAL.PA

Valbiotis SA Debt to Equity Ratio for the year ending December 31, 2023: 0.35

Valbiotis SA Debt to Equity Ratio is 0.35 for the year ending December 31, 2023, a -34.89% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • Valbiotis SA Debt to Equity Ratio for the year ending December 31, 2022 was 0.54, a 1.05% change year over year.
  • Valbiotis SA Debt to Equity Ratio for the year ending December 31, 2021 was 0.53, a -46.20% change year over year.
  • Valbiotis SA Debt to Equity Ratio for the year ending December 31, 2020 was 0.99, a 70.42% change year over year.
  • Valbiotis SA Debt to Equity Ratio for the year ending December 31, 2019 was 0.58, a 53.84% change year over year.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
SV Wall Street
Paris Stock Exchange: ALVAL.PA

Valbiotis SA

CEO Mr. Sebastien Peltier HDR, Ph.D.
IPO Date June 7, 2017
Location France
Headquarters rue Paul Vatine
Employees 52
Sector Health Care
Industries
Pharmaceuticals Biotechnology Clinical Trials Research & Consulting
Description

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.

Similar companies

OSE.PA

OSE Immunotherapeutics SA

USD 6.91

1.86%

StockViz Staff

January 31, 2025

Any question? Send us an email